4534 Mochida Pharmaceutical Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4534

TSE Prime

Mochida Pharmaceutical Co.,Ltd.

3,100

JPY

-40

(-1.27%)

Apr 24, 3:02 pm JST

21.70

USD

Apr 24, 2:02 am EDT

Result

PTS

outside of trading hours

3,097

Apr 24, 2:29 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	102,995	12,003	12,260	8,587	222.3	90	May 14, 2021	J-GAAP
Mar, 2022	110,179	14,392	14,799	10,569	277.4	90	May 13, 2022	J-GAAP
Mar, 2023	103,261	8,507	9,085	6,649	178.9	80	May 15, 2023	J-GAAP
Mar, 2024	102,885	5,802	6,037	4,547	126.8	80	May 13, 2024	J-GAAP
Mar, 2025 Guidance	106,000	7,500	7,700	5,600	158.0	80	May 13, 2024	J-GAAP
YoY	+3.0%	+29.3%	+27.5%	+23.2%	+24.6%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 13, 2019	103,000	7,700	8,100	5,800	80*	J-GAAP
	Mar 30, 2020	101,000	7,000	7,400	3,200	80*	J-GAAP
	Apr 24, 2020	101,700	8,700	9,100	4,500	80*	J-GAAP
Results	May 15, 2020	101,799	8,807	9,154	4,598	80*	J-GAAP
Mar, 2021	May 15, 2020	Available in future release
	Feb 1, 2021
	May 10, 2021
Results	May 14, 2021
Mar, 2022	May 14, 2021
	Nov 5, 2021
	Jan 31, 2022
Results	May 13, 2022
Mar, 2023	May 13, 2022
Results	May 15, 2023
Mar, 2024	May 15, 2023
	Feb 5, 2024
Results	May 13, 2024
Mar, 2025	May 13, 2024	106,000	7,500	7,700	5,600	80	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	62,644	+1.3	Available in future release
Mar, 2001	64,111	+2.3
Mar, 2002	63,348	-1.2
Mar, 2003	63,540	+0.3
Mar, 2004	64,254	+1.1
Mar, 2005	68,041	+5.9
Mar, 2006	70,627	+3.8
Mar, 2007	74,066	+4.9
Mar, 2008	74,573	+0.7
Mar, 2009	75,181	+0.8
Mar, 2010	78,549	+4.5
Mar, 2011	79,506	+1.2
Mar, 2012	86,205	+8.4
Mar, 2013	89,210	+3.5
Mar, 2014	93,947	+5.3
Mar, 2015	87,252	-7.1
Mar, 2016	92,272	+5.8
Mar, 2017	97,349	+5.5
Mar, 2018	106,761	+9.7
Mar, 2019	109,643	+2.7
Mar, 2020	101,799	-7.2
Mar, 2021	102,995	+1.2
Mar, 2022	110,179	+7.0
Mar, 2023	103,261	-6.3
Mar, 2024	102,885	-0.4
Mar, 2025 Guidance	106,000	+3.0	7,500	+29.3	7,700	+27.5	158.0	+24.6

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	103,261	8,507	8.24	5.21	4.13	0.64	178.9
Mar, 2024	102,885	5,802	5.64	3.57	2.86	0.65	126.8
Mar, 2025 Guidance	106,000	7,500	7.08	4.30	3.37	0.64	158.0

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	110,179	16,600	16,799	10,569	277.4
Fiscal Year	Mar, 2022	Mar, 2014	Mar, 2014	Mar, 2022	Mar, 2022

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	56,170	8,261	8,422	5,653	148.4	50	May 13, 2022	J-GAAP
Oct - Mar, 2022	50,061	3,228	3,642	2,726	73.4	40	May 15, 2023	J-GAAP
Oct - Mar, 2023	53,409	1,850	1,984	1,709	47.7	40	May 13, 2024	J-GAAP
Oct - Mar, 2024 Guidance	54,904	3,707	3,621	2,775	78.3	40	Nov 1, 2024	J-GAAP
YoY	+2.8%	+100.4%	+82.5%	+62.4%	+64.2%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	14,392	5,452	7,459	-2,007	-5,956	40,515	24.83	J-GAAP
Mar, 2023	8,507	4,348	7,297	-2,949	-6,884	38,010	23.93	J-GAAP
Mar, 2024	5,802	-7,406	-7,480	74	-6,393	24,290	15.30	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	81,394	10,356	10,639	8,081	216.5	117.1	Feb 6, 2023	J-GAAP
Apr - Dec, 2023	78,218	5,791	6,059	4,444	123.5	100.4	Feb 5, 2024	J-GAAP
Apr - Dec, 2024	80,731	7,243	7,640	5,605	158.1	99.2	Feb 7, 2025	J-GAAP
YoY	+3.2%	+25.1%	+26.1%	+26.1%	+28.0%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2023	21,867	-1,849	-1,554	-1,432	-38.5	-8.5	May 15, 2023	J-GAAP
Apr - Jun, 2023	24,747	2,515	2,592	1,688	46.2	10.2	Aug 4, 2023	J-GAAP
Jul - Sep, 2023	24,729	1,437	1,461	1,150	31.8	5.8	Nov 2, 2023	J-GAAP
Oct - Dec, 2023	28,742	1,839	2,006	1,606	44.6	6.4	Feb 5, 2024	J-GAAP
Jan - Mar, 2024	24,667	11	-22	103	2.9	0.0	May 13, 2024	J-GAAP
Apr - Jun, 2024	25,407	2,189	2,367	1,554	43.9	8.6	Aug 2, 2024	J-GAAP
Jul - Sep, 2024	25,689	1,604	1,712	1,271	35.9	6.2	Nov 1, 2024	J-GAAP
Oct - Dec, 2024	29,635	3,450	3,561	2,780	78.4	11.6	Feb 7, 2025	J-GAAP
YoY	+3.1%	+87.6%	+77.5%	+73.1%	+75.8%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2020	22,702	+3.2	Available in future release
Apr - Jun, 2020	27,379	+3.4
Jul - Sep, 2020	24,244	-3.1
Oct - Dec, 2020	28,258	+2.4
Jan - Mar, 2021	23,114	+1.8
Apr - Jun, 2021	27,362	-0.1
Jul - Sep, 2021	26,647	+9.9
Oct - Dec, 2021	30,805	+9.0
Jan - Mar, 2022	25,365	+9.7
Apr - Jun, 2022	27,692	+1.2
Jul - Sep, 2022	25,508	-4.3
Oct - Dec, 2022	28,194	-8.5
Jan - Mar, 2023	21,867	-13.8
Apr - Jun, 2023	24,747	-10.6
Jul - Sep, 2023	24,729	-3.1
Oct - Dec, 2023	28,742	+1.9
Jan - Mar, 2024	24,667	+12.8
Apr - Jun, 2024	25,407	+2.7
Jul - Sep, 2024	25,689	+3.9
Oct - Dec, 2024	29,635	+3.1	3,450	+87.6	3,561	+77.5	78.4	+75.8

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	30,805	6,914	7,070	5,843	147.2
Fiscal Year	Dec, 2021	Dec, 2021	Dec, 2021	Jun, 2018	Jun, 2018

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	3,424.21	78.9	163,139	128,646	121,668	ー	May 13, 2022	J-GAAP
Mar, 2023	3,470.18	79.8	158,831	126,775	118,943	ー	May 15, 2023	J-GAAP
Mar, 2024	3,609.64	80.6	158,800	127,967	117,022	ー	May 13, 2024	J-GAAP
Apr - Dec, 2024	ー	78.5	166,050	130,316	119,791	ー	Feb 7, 2025	J-GAAP

Mochida Pharmaceutical Co.,Ltd.(4534) Financial Results